VANDA PHARMACEUTICALS INC (VNDA) Stock Overview
NASDAQ:VNDA - US9216591084 - Common Stock
VNDA Key Statistics, Chart & Performance
The current stock price of VNDA is 4.67 USD. In the past month the price decreased by -0.21%. In the past year, price decreased by -11.72%.
VNDA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.68 | 368.08B | ||
| AMGN | AMGEN INC | 13.28 | 155.90B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.86 | 99.27B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 62.29B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.14B | ||
| ARGX | ARGENX SE - ADR | 76.39 | 43.34B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.24 | 36.72B | ||
| INSM | INSMED INC | N/A | 27.94B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.19B | ||
| NTRA | NATERA INC | N/A | 22.74B | ||
| BIIB | BIOGEN INC | 8.54 | 20.04B |
Related stock screener links
About VNDA
Company Profile
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 368 full-time employees. The company went IPO on 2006-04-12. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Company Info
VANDA PHARMACEUTICALS INC
Suite 300E, 2200 Pennsylvania Ave Nw
WASHINGTON WASHINGTON DC 20037 US
CEO: Mihael H. Polymeropoulos
Employees: 368
Phone: 12027343400
VANDA PHARMACEUTICALS INC / VNDA FAQ
What is the stock price of VANDA PHARMACEUTICALS INC today?
The current stock price of VNDA is 4.67 USD. The price increased by 1.3% in the last trading session.
What is the ticker symbol for VANDA PHARMACEUTICALS INC stock?
The exchange symbol of VANDA PHARMACEUTICALS INC is VNDA and it is listed on the Nasdaq exchange.
On which exchange is VNDA stock listed?
VNDA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VANDA PHARMACEUTICALS INC stock?
9 analysts have analysed VNDA and the average price target is 12.92 USD. This implies a price increase of 176.66% is expected in the next year compared to the current price of 4.67. Check the VANDA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VANDA PHARMACEUTICALS INC worth?
VANDA PHARMACEUTICALS INC (VNDA) has a market capitalization of 275.95M USD. This makes VNDA a Micro Cap stock.
How many employees does VANDA PHARMACEUTICALS INC have?
VANDA PHARMACEUTICALS INC (VNDA) currently has 368 employees.
What are the support and resistance levels for VANDA PHARMACEUTICALS INC (VNDA) stock?
VANDA PHARMACEUTICALS INC (VNDA) has a support level at 4.61 and a resistance level at 4.77. Check the full technical report for a detailed analysis of VNDA support and resistance levels.
Is VANDA PHARMACEUTICALS INC (VNDA) expected to grow?
The Revenue of VANDA PHARMACEUTICALS INC (VNDA) is expected to grow by 12.81% in the next year. Check the estimates tab for more information on the VNDA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VANDA PHARMACEUTICALS INC (VNDA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VNDA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VNDA, evaluating the profitability, health, valuation and growth aspects
- VANDA PHARMACEUTICALS INC (VNDA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VANDA PHARMACEUTICALS INC (VNDA) Sales and EPS estimates to see what analysts future expectations are.
- VANDA PHARMACEUTICALS INC (VNDA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VANDA PHARMACEUTICALS INC (VNDA) Insider and Institutional Ownership to learn about the owners and their transactions.
- VANDA PHARMACEUTICALS INC (VNDA) Stock Chart to make your own analysis
- VANDA PHARMACEUTICALS INC (VNDA) Latest news and press-releases to stay up to date.
Does VANDA PHARMACEUTICALS INC (VNDA) stock pay dividends?
VNDA does not pay a dividend.
When does VANDA PHARMACEUTICALS INC (VNDA) report earnings?
VANDA PHARMACEUTICALS INC (VNDA) will report earnings on 2025-11-04.
What is the Price/Earnings (PE) ratio of VANDA PHARMACEUTICALS INC (VNDA)?
VANDA PHARMACEUTICALS INC (VNDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.13).
What is the Short Interest ratio of VANDA PHARMACEUTICALS INC (VNDA) stock?
The outstanding short interest for VANDA PHARMACEUTICALS INC (VNDA) is 8.29% of its float. Check the ownership tab for more information on the VNDA short interest.
VNDA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to VNDA. When comparing the yearly performance of all stocks, VNDA is a bad performer in the overall market: 73.08% of all stocks are doing better.
VNDA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VNDA. VNDA has a medium profitability rating, but doesn't score so well on its financial health evaluation.
VNDA Financial Highlights
Over the last trailing twelve months VNDA reported a non-GAAP Earnings per Share(EPS) of -1.13. The EPS decreased by -494.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.71% | ||
| ROE | -13.76% | ||
| Debt/Equity | 0.01 |
VNDA Forecast & Estimates
9 analysts have analysed VNDA and the average price target is 12.92 USD. This implies a price increase of 176.66% is expected in the next year compared to the current price of 4.67.
For the next year, analysts expect an EPS growth of -475.88% and a revenue growth 12.81% for VNDA